TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30983387

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation plus nine months after‐care with face‐to‐face group lifestyle counseling
Number of subjects: 740

Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation plus nine months after‐care with individual lifestyle telephone counseling
Number of subjects: 740
Study: 30015674

Group type: EXPERIMENTAL
Intervention: Abdominal Girth (AG) measurement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gastric Residual Volumes (GRV) assessment
Number of subjects: 0
Study: 27358255

Group type: EXPERIMENTAL
Intervention: Intrauterine instillation of levobupivacaine
Number of subjects: 438

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 438
Study: 25087311

Group type: EXPERIMENTAL
Intervention: Pentavac administered second (Group A)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Pentavac administered first (Group B)
Number of subjects: 184
Study: 22058086

Group type: EXPERIMENTAL
Intervention: Silymarin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19039304

Group type: EXPERIMENTAL
Intervention: [(99m)Tc]HYNIC annexin V (treated group)
Number of subjects: 11

Group type: COMPARATOR
Intervention: [(99m)Tc]HYNIC annexin V (control group)
Number of subjects: 11
Study: 17925179

Group type: EXPERIMENTAL
Intervention: Stimulation of posterior cord
Number of subjects: 70

Group type: COMPARATOR
Intervention: Stimulation of lateral cord
Number of subjects: 70
Study: 15010066

Group type: EXPERIMENTAL
Intervention: Glufosfamide 5000 mg/m² by 1-hour intravenous infusion every 3 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Hydration (randomised group)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 39
Study: 11758323

Group type: EXPERIMENTAL
Intervention: Infiltration of 0.5% bupivacaine into the surgical wound before surgery combined with general anesthesia (Group L)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia combined with general anesthesia (Group E)
Number of subjects: 45

Group type: COMPARATOR
Intervention: General anesthesia only (Group C)
Number of subjects: 45
Study: 9683329

Group type: EXPERIMENTAL
Intervention: High Protein Meal (HP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High Carbohydrate Meal (HC)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High Fat Meal (HF)
Number of subjects: 10
Study: 7885940

Group type: EXPERIMENTAL
Intervention: Fast chronotropic response pattern
Number of subjects: 13

Group type: COMPARATOR
Intervention: Linear chronotropic response pattern
Number of subjects: 13

Group type: COMPARATOR
Intervention: Slow chronotropic response pattern
Number of subjects: 13
Study: 3381964

Group type: EXPERIMENTAL
Intervention: Restrictive diet (advice to restrict intake of red meat and peroxidase-containing vegetables)
Number of subjects: 786

Group type: COMPARATOR
Intervention: No diet (control group)
Number of subjects: 786
Study: 30908574

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Paracetamol responders
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Paracetamol nonresponders
Number of subjects: 47
Study: 29550881

Group type: EXPERIMENTAL
Intervention: Nabilone (0.5 mg/2 weeks followed by 1.0 mg/6 weeks)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 28873768

Group type: EXPERIMENTAL
Intervention: Interactive web‐based mobile reminder calendar
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 25785695

Group type: EXPERIMENTAL
Intervention: Experimental group (taught on day 1 and tested on days 10, 20, and 30)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (taught on day 1 and tested for proficiency on day 30)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 23302446

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens 0.625 mg/day for 4 weeks with antipsychotic treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo booster with antipsychotics
Number of subjects: 32
Study: 21971661

Group type: EXPERIMENTAL
Intervention: Propofol (Group GP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sevoflurane (Group GS)
Number of subjects: 20
Study: 18979881

Group type: EXPERIMENTAL
Intervention: Recurrent Nuss procedure
Number of subjects: 21

Group type: COMPARATOR
Intervention: Recurrent Ravitch procedure
Number of subjects: 21

Group type: COMPARATOR
Intervention: Primary Nuss procedure
Number of subjects: 21
Study: 16531920

Group type: EXPERIMENTAL
Intervention: Tc‐sestamibi
Number of subjects: 29
Study: 14652528

Group type: EXPERIMENTAL
Intervention: Exercise with music
Number of subjects: 33

Group type: COMPARATOR
Intervention: Exercise without music (control)
Number of subjects: 33
Study: 15806975

Group type: EXPERIMENTAL
Intervention: Shenfu injection (SFI) plus stanozol and cyclosporin A
Number of subjects: 60

Group type: COMPARATOR
Intervention: Stanozol and cyclosporin A alone (Control)
Number of subjects: 60
Study: 10613172

Group type: EXPERIMENTAL
Intervention: Low intensity ultrasound
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7574195

Group type: EXPERIMENTAL
Intervention: Azithromycin prophylaxis (250 mg/d) for cohort 1, administered as 500 mg on day 14 before challenge, followed by 250 mg/d from day 13 before challenge through day 7 after challenge.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Azithromycin prophylaxis (250 mg/d) for cohort 2, continued for 28 days after the challenge.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no treatment) for both cohorts.
Number of subjects: 24
Study: 2037705

Group type: EXPERIMENTAL
Intervention: Pinacidil (0.1 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pinacidil (0.1 mg/kg) with propranolol pretreatment
Number of subjects: 0
Study: 7308332

Group type: EXPERIMENTAL
Intervention: 8 mg bromhexine (4 mg in two patients)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31124581

Group type: EXPERIMENTAL
Intervention: Medac Escherichia coli asparaginase
Number of subjects: 599

Group type: COMPARATOR
Intervention: Erwinia asparaginase
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Dexamethasone (6 mg/m²/day)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Prednisolone (60 mg/m²/day)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Intensified CNS-directed therapy
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Intensified induction chemotherapy
Number of subjects: 599
Study: 29032379

Group type: EXPERIMENTAL
Intervention: Oral bicarbonate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 25592094

Group type: EXPERIMENTAL
Intervention: Interval Training (IT)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Continuous Training (CT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both IT and CT
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Interval Training (IT) vs Continuous Training (CT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No specific intervention
Number of subjects: 41
Study: 24673168

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient powder (MNP) plus early learning (integrated intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MNP alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo plus early learning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21102344

Group type: COMPARATOR
Intervention: Duloxetine (placebo-controlled)
Number of subjects: 3266
Study: 19725342

Group type: EXPERIMENTAL
Intervention: Sugammadex administered at a dosage of 2 mg x kg(‐1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propofol anesthesia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 20
Study: 18027087

Group type: EXPERIMENTAL
Intervention: Doxorubicin (restricted to 30% of patients with advanced/aggressive disease)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Post-operative radiation therapy (largely eliminated)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Comparative treatment regimens (randomized trials)
Number of subjects: 350
Study: 15130189

Group type: EXPERIMENTAL
Intervention: Balanced and complementary processing of text/adjunct information
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-complementary processing
Number of subjects: 80
Study: 11159473

Group type: EXPERIMENTAL
Intervention: Torque suturing technique
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Antitorque suturing technique
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: No torque suturing technique
Number of subjects: 53
Study: 9771153

Group type: EXPERIMENTAL
Intervention: Follow-up phone call by a breast care nurse (Group II, n = 366)
Number of subjects: 717

Group type: COMPARATOR
Intervention: No further intervention (Group I, n = 351)
Number of subjects: 717
Study: 8091361

Group type: EXPERIMENTAL
Intervention: SR 25776 500 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: triazolam 0.25 mg
Number of subjects: 8
Study: 31900963

Group type: EXPERIMENTAL
Intervention: Progression of disease
Number of subjects: 1607

Group type: COMPARATOR
Intervention: Stable disease
Number of subjects: 1607

Group type: EXPERIMENTAL
Intervention: Risk stratification
Number of subjects: 1607

Group type: EXPERIMENTAL
Intervention: Factors associated with time to progression
Number of subjects: 1607

Group type: EXPERIMENTAL
Intervention: Post-surgery progression
Number of subjects: 1607
Study: 30460402

Group type: EXPERIMENTAL
Intervention: Tonsillectomy plus platelet-rich plasma (PRP) therapy (TPRP group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Tonsillectomy alone (TA group)
Number of subjects: 80
Study: 28870263

Group type: EXPERIMENTAL
Intervention: 3000 IU vitamin D3 taken daily from randomization in pregnancy until trial discharge at 12 months postpartum
Number of subjects: 2300

Group type: COMPARATOR
Intervention: Matching placebo regimen
Number of subjects: 2300
Study: 26254953

Group type: EXPERIMENTAL
Intervention: Indoor hand-bike exercise program (60-minute sessions, 3 times per week for 6 weeks)
Number of subjects: 15
Study: 23335291

Group type: EXPERIMENTAL
Intervention: Nurse home visitation intervention
Number of subjects: 429

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 429
Study: 21943365

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI) colonoscopy
Number of subjects: 482

Group type: COMPARATOR
Intervention: Conventional colonoscopy
Number of subjects: 482
Study: 18306007

Group type: EXPERIMENTAL
Intervention: Closed-circuit anesthesia (CCA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Heat moisture exchangers (HMEs) in CCA
Number of subjects: 40

Group type: COMPARATOR
Intervention: Semi-closed anesthesia (SCA)
Number of subjects: 40
Study: 16569797

Group type: EXPERIMENTAL
Intervention: Divalproex sodium delayed-release (DR)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Divalproex sodium extended-release (ER)
Number of subjects: 28
Study: 14507845

Group type: EXPERIMENTAL
Intervention: Consideration of oocyte donation
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Opposition to oocyte donation
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Doubt about oocyte donation
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Factors increasing willingness to donate
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Feelings about helping childless couples
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Contact with offspring
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Importance of genetic link
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Parental status of potential donors
Number of subjects: 1000
Study: 11246599

Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/drospirenone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Marvelon (ethinylestradiol/desogestrel)
Number of subjects: 0
Study: 8721265

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (160 mg/d)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 1551152

Group type: EXPERIMENTAL
Intervention: Rectal ibuprofen (40 mg.kg‐1.day‐1 in divided doses)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 3565028

Group type: EXPERIMENTAL
Intervention: 6 Lf tetanus toxoid
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: 6 Lf tetanus toxoid combined with 2 Lf diphtheria toxoid
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: 6 Lf tetanus toxoid combined with 5 Lf diphtheria toxoid
Number of subjects: 237

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 237
Study: 31233117

Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs) in primary care
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard of care (SOC) at local hospital
Number of subjects: 140
Study: 29688793

Group type: COMPARATOR
Intervention: High-dose BNR (BNR-H, 1010 CFU/day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Low-dose BNR (BNR-L, 109 CFU/day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: COMPARATOR
Intervention: Biochemical parameters
Number of subjects: 90
Study: 26456200

Group type: EXPERIMENTAL
Intervention: Intra-arterial therapy (IA therapy)
Number of subjects: 517
Study: 24866496

Group type: EXPERIMENTAL
Intervention: Moderate dose resveratrol (300mg/day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High dose resveratrol (1000mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 22702148

Group type: EXPERIMENTAL
Intervention: Visual-analogue scale (VAS) for anxiety assessment
Number of subjects: 156
Study: 20461567

Group type: EXPERIMENTAL
Intervention: PDA-based SCC tool
Number of subjects: 100

Group type: COMPARATOR
Intervention: Paper-based reminder tool
Number of subjects: 100
Study: 18478253

Group type: EXPERIMENTAL
Intervention: ST + IMT (Inspiratory Muscle Training at 80% SMIP, 3 days/week)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ST + SHAM-IMT (Sham Inspiratory Muscle Training)
Number of subjects: 30

Group type: COMPARATOR
Intervention: ST (Swim Training only)
Number of subjects: 30
Study: 15813664

Group type: EXPERIMENTAL
Intervention: Formoterol HFA (Oxis) 2 x 4.5microg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Albuterol HFA (Ventoline) 2 x 100microg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12500859

Group type: EXPERIMENTAL
Intervention: Repeated practice in color discrimination tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Category learning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hue- and lightness-based category learning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 10711985

Group type: EXPERIMENTAL
Intervention: Duchenne and Becker dystrophies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Limb girdle muscular dystrophies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distal myopathies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Congenital muscular dystrophies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fukuyama congenital muscular dystrophy
Number of subjects: 0
Study: 7791594

Group type: EXPERIMENTAL
Intervention: Exerstriders (E)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 20
Study: 1646240

Group type: EXPERIMENTAL
Intervention: Fosinopril sodium (SQ 28,555) 10 to 640 mg once daily for 3 days
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Fosinopril sodium (SQ 28,555) 80 mg bid and 160 mg bid for 2 weeks
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Fosinopril sodium (SQ 28,555)
Number of subjects: 73
Study: 6274372

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate combined with antacid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atropine combined with antacid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline combined with antacid
Number of subjects: 0
Study: 30902761

Group type: EXPERIMENTAL
Intervention: Conservative surgery (27 cases)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radical surgery (33 cases)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: KESS scores < 10 (reference)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: KESS scores between 10 and 17
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: KESS scores > 17
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overall gastrointestinal, quality of life and urinary scores after surgery
Number of subjects: 60
Study: 29912399

Group type: EXPERIMENTAL
Intervention: Ceftazidime/avibactam
Number of subjects: 1146

Group type: COMPARATOR
Intervention: Comparator (predominantly carbapenem)
Number of subjects: 1146
Study: 26670162

Group type: EXPERIMENTAL
Intervention: Screening for gestational diabetes mellitus in primary care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening for gestational diabetes mellitus in secondary care
Number of subjects: 0

Group type: COMPARATOR
Intervention: No screening
Number of subjects: 0
Study: 25369243

Group type: EXPERIMENTAL
Intervention: Atomoxetine 1.2 mg/kg/day
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 22703757

Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 90 mg
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 20590389

Group type: EXPERIMENTAL
Intervention: Ferguson operation with RF scalpel (group A)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Traditional diathermy (group B)
Number of subjects: 28
Study: 18343939

Group type: EXPERIMENTAL
Intervention: Spirulina
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15849873

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) with weak complex waveform fields
Number of subjects: 89

Group type: COMPARATOR
Intervention: Sham-field control group
Number of subjects: 89
Study: 12823907

Group type: EXPERIMENTAL
Intervention: Diskus inhaler
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Turbuhaler
Number of subjects: 0

Group type: COMPARATOR
Intervention: pMDI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dry powder inhalers (DPIs)
Number of subjects: 0
Study: 10393682

Group type: EXPERIMENTAL
Intervention: Ganciclovir
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Ganciclovir (no calcium blockers)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo (no calcium blockers)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Ganciclovir (with calcium blockers)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo (with calcium blockers)
Number of subjects: 149
Study: 8707991

Group type: EXPERIMENTAL
Intervention: Behavioural self-management plus positive reinforcement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basic oral hygiene instructions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Performance feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behavioural self-management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Positive reinforcement
Number of subjects: 0
Study: 1906164

Group type: EXPERIMENTAL
Intervention: Early discharge care model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Institutional benefits
Number of subjects: 0
Study: 6663640

Group type: EXPERIMENTAL
Intervention: Two therapists, long-term
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One therapist, long-term
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two therapists, intensive
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 0
Study: 31415660

Group type: EXPERIMENTAL
Intervention: Complimentary counseling and educational support regarding EDOs
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 1053
Study: 25679310

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy combined with two cycles of concomitant cisplatin
Number of subjects: 224

Group type: COMPARATOR
Intervention: Hyperfractionated radiation therapy alone
Number of subjects: 224
Study: 24019259

Group type: EXPERIMENTAL
Intervention: KB001 10 mg/kg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: KB001 3 mg/kg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 23102241

Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy (group A, n = 261)
Number of subjects: 521

Group type: COMPARATOR
Intervention: Placebo (group B, n = 260)
Number of subjects: 521

Group type: COMPARATOR
Intervention: Non-H. pylori-eradicated cases (group B, n = 260)
Number of subjects: 521
Study: 19573883

Group type: EXPERIMENTAL
Intervention: Endurance training (12 weeks, 5 days/week, 1 hour/day, 65% peak oxygen consumption)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 10
Study: 17907485

Group type: EXPERIMENTAL
Intervention: Silane application with Single Bond adhesive
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrofluoric acid-etching and silane application with Clearfil Photo Bond adhesive
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No treatment with Clearfil New Bond adhesive
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 15050375

Group type: EXPERIMENTAL
Intervention: Rapid stream stimulation paradigm (RSS) with a high rate of presentation (250 ms) and a minimum of two background stimuli preceding each word.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard paradigms such as rapid serial visual presentation without interspersed background stimuli.
Number of subjects: 0
Study: 10753983

Group type: EXPERIMENTAL
Intervention: Warfarin (2 mg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Combination of 1 mg warfarin plus 300 mg aspirin
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Combination of 2 mg warfarin plus 300 mg aspirin
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Adjusted-dose warfarin (INR 2.0 to 3.0)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Healthy control subjects in sinus rhythm
Number of subjects: 61